HIV-1 drug resistance profiles in children and adults with viral load of

Monika Hermankova, Stuart Campbell Ray, Christian Ruff, Monique Powell-Davis, Roxann Ingersoll, Richard T. D'Aquila, Thomas C Quinn, Janet M Siliciano, Robert F Siliciano, Deborah Persaud

Research output: Contribution to journalArticle

Abstract

Context: The continued release of human immunodeficiency virus type 1 (HIV-1) into plasma at very low levels during highly active antiretroviral therapy (HAART) can be detected using specialized techniques, but the nature and significance of this low-level viremia, especially as related to acquisition of drug resistance mutations, are unclear. Objective: To determine genetic resistance profiles of low-level plasma HIV-1 in patients with prolonged viral suppression (+ T cells and plasma H IV for 7 of 10 patients and showed patient-specific clustering of sequences and a close relationship between virus in te plasma and the latent reservoir. Conclusions: Based on the samples that could be amplified, low-level viremia in children and adults receiving HAART with prolonged suppression of viremia to less than 50 copies/mL of HIV-1 RNA may result primarily from archival, pre-HAART virus, reflecting earlier treatment conditions, and does not appear to require development of new, HAART-selected mutations reflecting partial resistance to therapy. Low-level viremia below 50 copies/mL may represent less of a concern regarding impending drug failure of current HAART regimens. However, the archival drug-resistant virus may be relevant regarding future treatment strategies.

Original languageEnglish (US)
Pages (from-to)196-207
Number of pages12
JournalJournal of the American Medical Association
Volume286
Issue number2
StatePublished - 2001

Fingerprint

Highly Active Antiretroviral Therapy
Viral Load
Drug Resistance
Viremia
HIV-1
Viruses
Mutation
Pharmaceutical Preparations
Cluster Analysis
Therapeutics
RNA
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hermankova, M., Ray, S. C., Ruff, C., Powell-Davis, M., Ingersoll, R., D'Aquila, R. T., ... Persaud, D. (2001). HIV-1 drug resistance profiles in children and adults with viral load of . Journal of the American Medical Association, 286(2), 196-207.

HIV-1 drug resistance profiles in children and adults with viral load of . / Hermankova, Monika; Ray, Stuart Campbell; Ruff, Christian; Powell-Davis, Monique; Ingersoll, Roxann; D'Aquila, Richard T.; Quinn, Thomas C; Siliciano, Janet M; Siliciano, Robert F; Persaud, Deborah.

In: Journal of the American Medical Association, Vol. 286, No. 2, 2001, p. 196-207.

Research output: Contribution to journalArticle

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT et al. HIV-1 drug resistance profiles in children and adults with viral load of . Journal of the American Medical Association. 2001;286(2):196-207.
Hermankova, Monika ; Ray, Stuart Campbell ; Ruff, Christian ; Powell-Davis, Monique ; Ingersoll, Roxann ; D'Aquila, Richard T. ; Quinn, Thomas C ; Siliciano, Janet M ; Siliciano, Robert F ; Persaud, Deborah. / HIV-1 drug resistance profiles in children and adults with viral load of . In: Journal of the American Medical Association. 2001 ; Vol. 286, No. 2. pp. 196-207.
@article{793be34205ad4eef85486ff1f79efe73,
title = "HIV-1 drug resistance profiles in children and adults with viral load of",
abstract = "Context: The continued release of human immunodeficiency virus type 1 (HIV-1) into plasma at very low levels during highly active antiretroviral therapy (HAART) can be detected using specialized techniques, but the nature and significance of this low-level viremia, especially as related to acquisition of drug resistance mutations, are unclear. Objective: To determine genetic resistance profiles of low-level plasma HIV-1 in patients with prolonged viral suppression (+ T cells and plasma H IV for 7 of 10 patients and showed patient-specific clustering of sequences and a close relationship between virus in te plasma and the latent reservoir. Conclusions: Based on the samples that could be amplified, low-level viremia in children and adults receiving HAART with prolonged suppression of viremia to less than 50 copies/mL of HIV-1 RNA may result primarily from archival, pre-HAART virus, reflecting earlier treatment conditions, and does not appear to require development of new, HAART-selected mutations reflecting partial resistance to therapy. Low-level viremia below 50 copies/mL may represent less of a concern regarding impending drug failure of current HAART regimens. However, the archival drug-resistant virus may be relevant regarding future treatment strategies.",
author = "Monika Hermankova and Ray, {Stuart Campbell} and Christian Ruff and Monique Powell-Davis and Roxann Ingersoll and D'Aquila, {Richard T.} and Quinn, {Thomas C} and Siliciano, {Janet M} and Siliciano, {Robert F} and Deborah Persaud",
year = "2001",
language = "English (US)",
volume = "286",
pages = "196--207",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - HIV-1 drug resistance profiles in children and adults with viral load of

AU - Hermankova, Monika

AU - Ray, Stuart Campbell

AU - Ruff, Christian

AU - Powell-Davis, Monique

AU - Ingersoll, Roxann

AU - D'Aquila, Richard T.

AU - Quinn, Thomas C

AU - Siliciano, Janet M

AU - Siliciano, Robert F

AU - Persaud, Deborah

PY - 2001

Y1 - 2001

N2 - Context: The continued release of human immunodeficiency virus type 1 (HIV-1) into plasma at very low levels during highly active antiretroviral therapy (HAART) can be detected using specialized techniques, but the nature and significance of this low-level viremia, especially as related to acquisition of drug resistance mutations, are unclear. Objective: To determine genetic resistance profiles of low-level plasma HIV-1 in patients with prolonged viral suppression (+ T cells and plasma H IV for 7 of 10 patients and showed patient-specific clustering of sequences and a close relationship between virus in te plasma and the latent reservoir. Conclusions: Based on the samples that could be amplified, low-level viremia in children and adults receiving HAART with prolonged suppression of viremia to less than 50 copies/mL of HIV-1 RNA may result primarily from archival, pre-HAART virus, reflecting earlier treatment conditions, and does not appear to require development of new, HAART-selected mutations reflecting partial resistance to therapy. Low-level viremia below 50 copies/mL may represent less of a concern regarding impending drug failure of current HAART regimens. However, the archival drug-resistant virus may be relevant regarding future treatment strategies.

AB - Context: The continued release of human immunodeficiency virus type 1 (HIV-1) into plasma at very low levels during highly active antiretroviral therapy (HAART) can be detected using specialized techniques, but the nature and significance of this low-level viremia, especially as related to acquisition of drug resistance mutations, are unclear. Objective: To determine genetic resistance profiles of low-level plasma HIV-1 in patients with prolonged viral suppression (+ T cells and plasma H IV for 7 of 10 patients and showed patient-specific clustering of sequences and a close relationship between virus in te plasma and the latent reservoir. Conclusions: Based on the samples that could be amplified, low-level viremia in children and adults receiving HAART with prolonged suppression of viremia to less than 50 copies/mL of HIV-1 RNA may result primarily from archival, pre-HAART virus, reflecting earlier treatment conditions, and does not appear to require development of new, HAART-selected mutations reflecting partial resistance to therapy. Low-level viremia below 50 copies/mL may represent less of a concern regarding impending drug failure of current HAART regimens. However, the archival drug-resistant virus may be relevant regarding future treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=0034946886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034946886&partnerID=8YFLogxK

M3 - Article

C2 - 11448283

AN - SCOPUS:0034946886

VL - 286

SP - 196

EP - 207

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 2

ER -